



ASX ANNOUNCEMENT

21 November 2024

Opyl Signs Service Level Agreement with Southern Clinical Development Consulting (Southern CDC)

Melbourne, Australia – Opyl Limited (ASX: OPL), a leader in AI-driven clinical trial design and optimisation, has signed a Service Level Agreement (SLA) with Southern Clinical Development Consulting (Southern CDC). This agreement licenses Opyl's TrialKey platform to Southern CDC, enhancing their clinical trial support and optimisation capabilities. OPL will receive fees for its services.

Key Highlights:

- **Data-Driven Reports:** Opyl will provide AI-powered insights via the TrialKey platform, offering predictive modelling and validation to support trial design and planning.
- **Revenue Per Report:** Opyl will receive a specified fee for each report under this agreement. The service fee is determined per project, offering flexibility in pricing based on the scope of services required.
- **Optimised Trial Planning:** TrialKey will assist Southern CDC in trial design, site feasibility, and patient recruitment strategies to support informed, data-driven decisions.
- **Sector Impact:** This agreement extends Opyl's role in clinical trial support, aligning with Southern CDC's mission to facilitate patient access to innovative treatments.

Southern CDC supports drug development across key therapeutic areas, including oncology, immunology, neurology, ophthalmology and infectious diseases, through early and late-stage clinical trials. The SLA enables Southern CDC to integrate TrialKey's insights for improved trial planning and execution.

Scope of AI-Driven Reporting

The TrialKey platform provides Southern CDC with comprehensive, data-rich reports. Reports cover:

Predictive Modelling and Validation: AI-driven simulations to refine trial design, incorporating extensive trial data for realistic outcome projections.



Competitor Analysis: In-depth comparison with similar trials to guide strategic planning and refine trial positioning.

Risk and Feasibility Assessment: Analysis of trial site options and risk factors, aiding in effective site selection and management.

Patient Recruitment Strategies: Insights on optimal patient recruitment pathways, tailored site selection, and retention strategies to meet enrolment targets efficiently.

Terms of Termination and Expiration

Under the agreement, Opyl will act as an independent contractor for a term of six (6) months which may be extended by mutual agreement.

Executive Commentary

Saurabh Jain, Executive Chairman of Opyl:

"We're pleased to see Southern CDC adopt our TrialKey platform, taking a step toward our broader strategy of partnering with CROs globally. Our goal is to make TrialKey an essential tool in every CRO's service offering, providing the kind of data-driven insights that both CROs and their clients increasingly rely on. As more CROs look to optimise trial design and efficiency, we believe TrialKey will become a standard, indispensable part of clinical trial management worldwide."

Dr Khalid Abubaker, Chief Operating Officer of Southern CDC:

"At Southern CDC, we are committed to advancing drug development and enhancing patient treatment through our tailored solutions. TrialKey's advanced analytics, unlocks new opportunities to refine trial designs, optimise site selections, and develop recruitment strategies that truly meet patient needs. This partnership empowers us to accelerate clinical trials for our sponsors, effectively addressing unmet medical needs with agility and precision. We're excited to jointly expedite the development of life-changing treatments, where every day counts."

About Southern Clinical Development Consulting (Southern CDC)

Southern Clinical Development Consulting is a dedicated service provider that supports drug development from pre-clinical stages to First-In-Human and late-stage trials. Southern CDC offers a comprehensive range of services, including biostatistical validation, vendor management,



strategic consultancy, site feasibility and management, and clinical operations support. Focused on areas such as oncology, ophthalmology, immunology, and neurology, Southern CDC partners with sponsors to deliver life-changing treatments through efficient and precise clinical trial frameworks.

This announcement has been authorised for release by the board

-ENDS-

For investor enquiries:

Bernice Averion
Head of Marketing and Communications
Phone: +61 415 311 957
Email: bernice.averion@opyl.ai

About Opyl Limited (ASX: OPL)

Opyl Limited is an AI company dedicated to leveraging data and technology to transform the landscape of clinical trials and medical research. With a commitment to innovation and strategic growth, Opyl is positioned to lead the way in shaping the future of healthcare solutions.